Ascendis Pharma Combination Therapy Shows Expanded Benefits in Achondroplasia Trial
Event summary
- Week 52 data from Ascendis Pharma's COACH trial showed combination therapy with TransCon CNP and TransCon hGH improved arm span, spinal canal dimensions, and leg alignment in children with achondroplasia.
- TransCon CNP treatment-naïve cohort saw a mean change in arm span Z-scores of +1.02, while TransCon CNP-treated cohort improved by +0.66.
- Combination therapy resulted in a mean change in tibial femoral angle (TFA) of -3.0 degrees compared to -1.3 degrees with monotherapy.
- All 21 children completed 52 weeks of treatment and remain on therapy in the ongoing Phase 2 trial.
The big picture
Ascendis Pharma's combination therapy approach represents a strategic shift in treating achondroplasia, moving beyond linear growth to address broader skeletal and neurological complications. The positive Week 52 data from the COACH trial positions the company to potentially expand its market reach in rare disease treatments, particularly as TransCon CNP gains regulatory approvals. The results also highlight the growing trend of combination therapies in addressing complex genetic conditions.
What we're watching
- Therapeutic Synergy
- How the combination of TransCon CNP and TransCon hGH will affect long-term outcomes in achondroplasia patients beyond linear growth.
- Regulatory Pathway
- Whether the expanded benefits observed will accelerate TransCon hGH's approval for achondroplasia in addition to its current indications.
- Market Differentiation
- The pace at which Ascendis can position this combination therapy as a best-in-class treatment option in the competitive rare disease space.